Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORPHEUS-Head and Neck Cancer phase 1b/2 umbrella study
MOH_2022-09-06_012032Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab and tiragolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Roche. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
atezolizumabtiragolumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2022-09-06_012032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-09-06_012032.